Immunotherapy for Metastatic Triple Negative Breast Cancer: Current Paradigm and Future Approaches.

ABSTRACT:

Opinion statement

In approximately 15-20% of the patients diagnosed with breast cancer, it comprises the triple negative (TN) subtype, which until recently lacked targets for specific treatments and is known for its aggressive clinical behavior in patients with metastatic disease. TNBC is considered the most immunogenic breast cancer subtype due to higher levels of tumor infiltrating lymphocytes (TILs), tumor mutational burden and PD-L1 expression, providing a rationale for immunotherapy. The addition of pembrolizumab to chemotherapy as first-line treatment resulted in significantly improved PFS and OS for PD-L1 positive mTNBC, leading to FDA approval. However, response rate of ICB in unselected patients is low. Ongoing (pre)clinical trials aim to further optimize ICB efficacy and

SUBMITTER: Geurts V 

PROVIDER: S-EPMC10172210 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature